nivolumab,visugromab
catal ym,bms
['nivo', 'nivolumab', 'catalym']
#catalym demonstrates clinical efficacy and tolerability in first-in-human phase 1 trial for #visugromab and #nivolumab combination #esmo22 
Follow top-line development in the oncology commercial domain. Gain entry to KOL discussions, including both medical professionals and business leaders.